XRAY earnings analysis
What we found in XRAY's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Dentsply Sirona reported Q1 2026 results featuring net sales of $880 million, surpassing estimates of $841 million, yet lagging on EPS at $0.27 against a forecasted $0.28. While revenue increased marginally year-over-year by 0.1%, the gross margin declined significantly to 48.5% from 53% a year prior, pointing to increasing cost pressures. The company reaffirmed guidance for 2026 net sales between $3.5 billion and $3.6 billion and adjusted EPS between $1.40 and $1.50.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Beat Estimates
- Actual Q1 2026 revenue reached $880 million, beating estimates of $841 million by 4.45%.
- EPS Below Expectations
- Reported EPS was $0.27, missing the estimated $0.28 by -3.57%.
- Cash Flow Improvement
- Operating cash flow improved to $40 million from $7 million year-over-year.
- Decline in Gross Margin
- Gross margin declined to 48.5%, down from 53% in the prior year.
- Increased Capital Expenditures
- Capex was $52 million, up from $19 million year-over-year.
- Revised Fiscal Year Guidance
- Maintained full-year sales guidance at $3.5B-$3.6B and EPS at $1.40-$1.50.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Significant Gross Margin Decline
- Gross margin decreased by 450 basis points to 48.5%, indicating rising cost pressures.
- Increased Restructuring Costs
- Restructuring expenses rose to $67 million from $9 million year-over-year.
- Negative EPS and Net Income
- Reported a net loss of $10 million compared to income of $20 million in the prior year.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.27
- Gross margin
- 48.5%
- Segment
- Connected Technology Solutions: $246M
- Segment
- Essential Dental Solutions: $350M
- Segment
- Orthodontic and Implant Solutions: $199M
- Segment
- Wellspect Healthcare: $85M
What they said about what is next.
Maintained outlook for 2026 net sales and adjusted EPS.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 8, 2025
- Dentsply Sirona reported net sales of $879 million for the three months ended March 31, 2025, down $74 million or 7.7% versus $953 million a year ago. Gross profit declined $40 million to $466 million (gross margin…
- 10-Q · May 2, 2024
- Dentsply Sirona reported net sales of $953 million for the quarter ended March 31, 2024, down $25 million (2.6%) versus the prior-year period; gross profit was $506 million and gross margin was flat at 53.1%. Net income…
- 10-K · February 29, 2024
- Dentsply Sirona reported 2023 net sales of $3,965 million (up from $3,922 million in 2022) and a reduced net loss of $132 million versus a $950 million loss in 2022. Management reports remediation of previously…
- 10-Q · August 7, 2023
- DENTSPLY SIRONA reported Q2 net sales of $1,028 million, up $5 million (0.5%) versus the prior year, driven by price increases, new products and 2.3% organic sales growth. Gross profit fell to $550 million (53.5% of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing XRAY makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever